155
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

Bilateral Occlusive Vasculitis Associated with Retinitis Pigmentosa - A Case Report

, DNB, , MS DNB, , DNB & , FRCS DNBORCID Icon
Pages 215-219 | Received 13 May 2021, Accepted 28 Sep 2021, Published online: 19 Nov 2021

References

  • Hartong DT, Berson EL, Dryja TP. Retinitis pigmentosa. Lancet. 2006 Nov 18;368(9549):1795–1809. doi:10.1016/S0140-6736(06)69740-7.
  • Bastek JV, Heckenlively JR, Straatsma BR. Cataract surgery in retinitis pigmentosa patients. Ophthalmology. 1982 Aug 1;89(8):880–884. doi:10.1016/S0161-6420(82)34700-4.
  • Balamurugan S, Das D, Hasanreisoglu M, et al. Interleukins and cytokine biomarkers in uveitis. Indian J Ophthalmol. 2020 Sep 1;68(9):1750. doi:10.4103/ijo.IJO_564_20.
  • Arden GB. The absence of diabetic retinopathy in patients with retinitis pigmentosa: implications for pathophysiology and possible treatment. British J Ophthalmol. 2001 Mar 1;85(3):366–370. doi:10.1136/bjo.85.3.366.
  • Sternberg P. The negative concidence of retinitis pigmentosa and proliferative diabetic retinopathy. Am J Ophthalmol. 1984;97:788–789. doi:10.1016/0002-9394(84)90518-X.
  • Spalton DJ, Bird AC, Cleary PE. Retinitis pigmentosa and retinal oedema. British J Ophthalmol. 1978 Mar 1;62(3):174–182. doi:10.1136/bjo.62.3.174.
  • Magliyah M, Alshamrani AA, Schatz P, Taskintuna I, Alzahrani Y, Nowilaty SR. Clinical spectrum, genetic associations and management outcomes of Coats-like exudative retinal vasculopathy in autosomal recessive retinitis pigmentosa. Ophthalmic Genet. 2021;42(2):178–185. doi:10.1080/13816810.2020.1867754.
  • Brown GC, Brown RH, Brown MM. Peripheral proliferative retinopathies. Int Ophthalmol. 1987;11(1):41–50. doi:10.1007/BF02027896.
  • Lu B, Yin H, Tang Q, et al. Multiple cytokine analyses of aqueous humor from the patients with retinitis pigmentosa. Cytokine. 2020 Mar;1(127):154943. doi:10.1016/j.cyto.2019.154943.
  • Kent D, Vinores SA, Campochiaro PA. Macular oedema: the role of soluble mediators. British J Ophthalmol. 2000 May 1;84(5):542–545. doi:10.1136/bjo.84.5.542.
  • Miyake K, Ibaraki N. Prostaglandins and cystoid macular edema. Surv Ophthalmol. 2002 Aug;1(47):S203–18. doi:10.1016/S0039-6257(02)00294-1.
  • Enea NA, Hollis TM, Kern JA, Gardner TW. Histamine H1 receptors mediate increased blood-retinal barrier permeability in experimental diabetes. Arch Ophthalmol. 1989 Feb 1;107(2):270–274. doi:10.1001/archopht.1989.01070010276036.
  • Kuijpers RW, Baarsma S, Van Hagen PM. Treatment of cystoid macular edema with octreotide. N Engl J Med. 1998 Feb 26;338(9):624–626. doi:10.1056/NEJM199802263380917.
  • Claudio L, Martiney JA, Brosnan CF. Ultrastructural studies of the blood-retina barrier after exposure to interleukin-1 beta or tumor necrosis factor-alpha. Lab Invest. 1994;70:850–861.
  • Strong S, Liew G, Michaelides M. Retinitis pigmentosa-associated cystoid macular oedema: pathogenesis and avenues of intervention. British J Ophthalmol. 2017 Jan 1;101(1):31–37. doi:10.1136/bjophthalmol-2016-309376.
  • Dutta Majumder P, Menia N, Roy R, et al. Uveitis in patients with retinitis pigmentosa: 30 years’ consecutive data. Ocul Immunol Inflamm. 2018;26(8):1283–1288. doi:10.1080/09273948.2017.1348527.
  • Hamel C. Retinitis pigmentosa. Orphanet J Rare Dis. 2006 Dec;1(1):1–2. doi:10.1186/1750-1172-1-40.
  • Chong NV, Bird AC. Management of inherited outer retinal dystrophies: present and future. British J Ophthalmol. 1999 Jan 1;83(1):120–122. doi:10.1136/bjo.83.1.120.
  • Hajali M, Fishman GA, Anderson RJ. The prevalence of cystoid macular oedema in retinitis pigmentosa patients determined by optical coherence tomography. Br J Ophthalmol. 2008;92(8):1065–1068. doi:10.1136/bjo.2008.138560.
  • Grover S, Apushkin MA, Fishman GA. Topical dorzolamide for the treatment of cystoid macular edema in patients with retinitis pigmentosa. Am J Ophthalmol. 2006;141(5):850–858. doi:10.1016/j.ajo.2005.12.030.
  • Acharya NR, Hong KC, Lee SM. Ranibizumab for refractory uveitis-related macular edema. Am J Ophthalmol. 2009 Aug 1;148(2):303–309. doi:10.1016/j.ajo.2009.03.028.
  • Salom D, Diaz-Llopis M, García-Delpech S, et al. Intravitreal ranibizumab in the treatment of cystoid macular edema associated with retinitis pigmentosa. J Ocul Pharmacol Ther. 2010 Oct 1;26(5):531–532. doi:10.1089/jop.2010.0044.
  • Triantafylla M, Massa HF, Dardabounis D, et al. Ranibizumab for the treatment of degenerative ocular conditions. Clin Ophthalmol. 2014;8:1187.
  • Radosavljevic A, Agarwal M, Bodaghi B, Smith JR, Zierhut M. Medical therapy of uveitic macular edema: biologic agents. Ocul Immunol Inflamm. 2020;28(8):1239–1250. doi:10.1080/09273948.2019.1709648.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.